Tardi PG - Search Results

1

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.

Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Dos Santos N, et al. Among authors: tardi pg. Biochim Biophys Acta. 2002 Apr 12;1561(2):188-201. doi: 10.1016/s0005-2736(02)00345-0. Biochim Biophys Acta. 2002. PMID: 11997119 Free article.

2

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.

Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Dos Santos N, et al. Among authors: tardi pg. J Control Release. 2005 Jun 20;105(1-2):89-105. doi: 10.1016/j.jconrel.2005.03.007. J Control Release. 2005. PMID: 15878792

3

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Tardi PG, et al. Biochim Biophys Acta. 2007 Mar;1768(3):678-87. doi: 10.1016/j.bbamem.2006.11.014. Epub 2006 Dec 6. Biochim Biophys Acta. 2007. PMID: 17208196 Free article.

4

Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Messerer CL, et al. Clin Cancer Res. 2004 Oct 1;10(19):6638-49. doi: 10.1158/1078-0432.CCR-04-0221. Clin Cancer Res. 2004. PMID: 15475454

5

In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.

Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. Webb MS, et al. Eur J Pharm Biopharm. 2007 Mar;65(3):289-99. doi: 10.1016/j.ejpb.2006.10.007. Epub 2006 Oct 17. Eur J Pharm Biopharm. 2007. PMID: 17123800

6

Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes.

Tardi P, Wan CP, Mayer L. Tardi P, et al. J Drug Target. 2016 Nov;24(9):797-804. doi: 10.1080/1061186X.2016.1184669. Epub 2016 May 16. J Drug Target. 2016. PMID: 27143215 Review.

7

Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes.

Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Longman SA, et al. Among authors: tardi pg. J Pharmacol Exp Ther. 1995 Dec;275(3):1177-84. J Pharmacol Exp Ther. 1995. PMID: 8531079

8

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB. Waterhouse DN, et al. Among authors: tardi pg. Drug Saf. 2001;24(12):903-20. doi: 10.2165/00002018-200124120-00004. Drug Saf. 2001. PMID: 11735647 Review.

9

Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes.

Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Harasym TO, et al. Bioconjug Chem. 1995 Mar-Apr;6(2):187-94. doi: 10.1021/bc00032a006. Bioconjug Chem. 1995. PMID: 7599262

10

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD. Tardi PG, et al. Mol Cancer Ther. 2009 Aug;8(8):2266-75. doi: 10.1158/1535-7163.MCT-09-0243. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters